Monitoring of heparin therapy during extracorporeal bypass: What are the remaining questions?;Surveillance de l'anticoagulation des circulations extracorporelles par l'héparine non fractionnée: Quels sont les probl̀emes non ŕesolus?

Annales Francaises d'Anesthesie et de Reanimation

Volumn 23, Issue 6, 2004, Pages 589-596

  Jude, B ^a   Lasne, D ^b   Mouton, C ^c   De Moerloose, P ^d  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Circulation extracorporelle; H parine; Surveillance biologique

Indexed keywords

HEPARIN;

ANTICOAGULATION; AUTOMATION; BIOLOGICAL MONITORING; BLOOD CLOTTING TIME; CLINICAL PROTOCOL; DRUG MONITORING; EXTRACORPOREAL CIRCULATION; HEART SURGERY; HEMOSTASIS; HEPARINIZATION; HUMAN; INSTRUMENTATION; LABORATORY; REVIEW;

EID: 3342899365     PISSN: 07507658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annfar.2004.02.047     Document Type: Short Survey

References (52)

1. Bevan D.H. Cardiac bypass haemostasis: putting blood through the mill. Br J Haematol. 104:1999;208-219
2. Chandler W.L., Velan T. Estimating the rate of thrombin and fibrin generation in vivo during cardiopulmonary bypass. Blood. 101:2003;4355-4362
3. Beijering R.J., Ten Cate H., Nurmohamed M.T., Ten Cate J.W. Anticoagulants and extracorporeal circuits. Semin Thromb Hemost. 23:1997;225-233
4. Hirsh J., Warkentin T.E., Shaughnessy S.G., Anand S., Halperin J.L., Raschke R., et al. Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 119:2001;64S-94S
5. Butterworth J., Lin Y.A., Prielipp R., Bennett J., James R. The pharmacokinetics and cardiovascular effects of a single intravenous dose of protamine in normal volunteers. Anesth. Analg. 94:2002;514-522
6. Malviya S. Monitoring and management of anticoagulation in children requiring extracorporeal circulation. Semin Thromb Hemost. 23:1997;563-567
7. Despotis G.J., Gravlee G., Filos K., Levy J. Anticoagulation monitoring during cardiac surgery. A review of current and emerging techniques. Anesthesiology. 91:1999;1122-1151
8. Bull B.S., Korpman R.A., Huse W.M., Briggs B.D. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg. 69:1975;674-684
9. Longrois D., Steib A. Exploration de l'hémostase au chevet du malade. Samama C.M., Hardy J.F., de Moerloose P., Sié P., Steib A. Hémorragies et thromboses périopératoires, approche pratique. 2000;17-34 Masson, Paris
10. Young J.A., Kisker T., Doty D.B. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg. 26:1978;31-40
11. Gravlee G.P., Case L.D., Angert K.C., Rogers A.T., Miller G.S. Variability of the activated coagulation time. Anesth Analg. 67:1988;469-472
12. Gravlee G.P., Haddon W.S., Rothberger H.K., Mills S.A., Rogers A.T., Bean V.E., et al. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation. J Thorac Cardiovasc Surg. 99:1990;518-527
13. Bélisle S., Hardy J.F., Martineau R. Effect of an excessively prolonged ACT during cardiopulmonary bypass and epsilon-aminocaproic acid on transfusion requirements after cardiac surgery. Anesth Analg. 90:(Suppl: 30):2000;62
14. Baufreton C. Réponse inflammatoire en chirurgie cardiaque : concepts et évolution des pratiques en circulation extracorporelle. STV. 13:2001;468-475
15. Ranucci M., Cazzaniga A., Soro G., Isgro G., Frigiola A., Menicanti L. The antithrombin III-saving effect of reduced systemic heparinization and heparin-coated circuits. J Cardiothorac Vasc Anesth. 16:2002;316-320
16. Aldea G.S., O'Gara P., Shapira O.M., Treanor P., Osman A., Patalis E., et al. Effect of anticoagulation protocol on outcome in patients undergoing CABG with heparin-bonded cardiopulmonary bypass circuits. Ann Thorac Surg. 65:1998;425-433
17. Shigeta O., Kojima H., Hiramatsu Y., Jikuya T., Terada Y., Atsumi N., et al. Low-dose protamine based on heparin-protamine titration method reduces platelet dysfunction after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 118:1999;354-360
18. Chu A.J., Wang Z.G., Raicu M., Beydoun S., Ramos N. Protamine inhibits tissue factor-initiated extrinsic coagulation. Br J Haematol. 115:2001;392-399
19. Hézard N., Metz D., Potron G., Nazeyrollas P., Maes D., Droulle C., et al. Monitoring the effect of heparin bolus during percutaneous coronary angioplasty (PTCA): assessment of bedside coagulation monitors. Thromb Haemost. 80:1998;865-866
20. Welsby I.J., McDonnell E., El-Moalem H., Stafford-Smith M., Toffaletti J.G. Activated clotting time systems vary in precision and bias and are not interchangeable when following heparin management protocols during cardiopulmonary bypass. J Clin Monit Comput. 17:2002;287-292
21. Wang J.S., Lin C.Y., Hung W.T., Thisted R.A., Karp R.B. In vitro effects of aprotinin on activated clotting time measured with different activators. J Thorac Cardiovasc Surg. 104:1992;1135-1140
22. Najman D.M., Walenga J.M., Fareed J., Pifarre R. Effects of aprotinin on anticoagulant monitoring. Implications in cardiovascular surgery. Ann Thorac Surg. 55:1993;662-666
23. Dietrich W., Dilthey G., Spannagl M., Jochum M., Braun S.L., Richter J.A. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. Anesthesiology. 83:1995;679-689
24. Bechtel J.F., Prosch J., Sievers H.H., Bartels C. Is the kaolin or celite activated clotting time affected by tranexamic acid? Ann Thorac Surg. 74:2002;390-393
25. Gravlee G.P., Whitaker C.L., Mark L.J., Rogers A.T., Royster R.L., Harrison G.A. Baseline activated coagulation time should be measured after surgical incision. Anesth Analg. 71:1990;549-553
26. Kesteven P.J., Pasaoglu I., Williams B.T., Savidge G.F. Significance of the whole blood activated clotting time in cardiopulmonary bypass. J Cardiovasc Surg. 27:1986;85-89
27. Moorehead M.T., Westengard J.C., Bull B.S. Platelet involvement in the activated coagulation time of heparinized blood. Anesth Analg. 63:1984;394-398
28. Moliterno D.J., Califf R.M., Aguirre F.V., Anderson K., Sigmon K.N., Weisman H.F. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Am J Cardiol. 75:1995;559-562
29. Hardy J.F., Bélisle S., Robitaille D., Perrault J., Roy M., Gagnon L. Measurement of heparin concentration in whole blood with the Hepcon/HMS device does not agree with laboratory determination of plasma heparin concentration using a chromogenic substrate for activated factor X. J Thorac Cardiovasc Surg. 112:1996;154-161
30. Horkay F., Martin P., Rajah S.M., Walker D.R. Response to heparinization in adults and children undergoing cardiac operations. Ann Thorac Surg. 53:1992;822-826
31. Yun J.H., Lee L.M., Wahr J.A., Fu B., Meyerhoff M.E., Yang V.C. Clinical application of disposable heparin sensors. Blood heparin measurements during open heart surgery. ASAIO J. 41:1995;661-664
32. Harloff M., Taraskiewicz J., Fotouhi C. Comparison study of the Hepcon system four and the hemostasis management system. Perfusion. 6:1991;297-301
33. Despotis G.J., Joist J.H., Goodnough L.T., Santoro S.A., Spitznagel E. Whole blood heparin concentration measurements by automated protamine titration agree with plasma anti-Xa measurements. J Thorac Cardiovasc Surg. 113:1997;611-613
34. Despotis G.J., Summerfield A.L., Joist J.H., Goodnough L.T., Santoro S.A., Spitznagel E., et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg. 108:1994;1076-1082
35. Culliford A.T., Gitel S.N., Starr N., Thomas S.T., Baumann F.G., Wessler S., et al. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. Ann Surg. 193:1981;105-111
36. Koster A., Fischer T., Praus M., Haberzettl H., Kuebler W.M., Hetzer R., et al. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management. Anesthesiology. 97:2002;837-841
37. Koster A., Fischer T., Gruendel M., Mappes A., Kuebler W.M., Bauer M., et al. Management of heparin resistance during cardiopulmonary bypass: The effect of five different anticoagulation strategies on hemostatic activation. J Cardiothorac Vasc Anesth. 17:2003;171-175
38. Levy J.H., Despotis G.J., Szlam F., Olson P., Meeker D., Weisiger A. Recombinant human transgenic antithrombin in cardiac surgery: a dose-finding study. Anesthesiology. 96:2002;1095-1102
39. Levine M.N., Hirsh J., Gent M., Turpie A.G., Cruickshank M., Weitz J., et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large doses of heparin. Arch Intern Med. 154:1994;49-56
40. Lemmer J.H., Despotis G.J. Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg. 123:2002;213-217
41. Slaughter T.F., Mark J.B., El-Moalem H., Hayward K.A., Hilton A.K., Hodgins L.P., et al. Hemostatic effects of antithrombin III supplementation during cardiac surgery: results of a prospective randomized investigation. Blood Coagul Fibrinolysis. 12:2001;25-31
42. Williams M.R., D'Ambra A.B., Beck J.R., Spanier T.B., Morales D.L., Helman D.N., et al. A randomized trial of antithrombin concentrate for treatment of heparin resistance. Ann Thor Surg. 70:2000;873-877
43. Despotis G.J., Levine V., Joist J.H., Joiner-Maier D., Spitznagel E. Antithrombin III during cardiac surgery. Effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation. Anesth Analg. 85:1997;498-506
44. Hashimoto K., Yamagishi M., Sasaki T., Nakano M., Kurosawa H. Heparin and antithrombin III levels during cardiopulmonary bypass: correlation with subclinical plasma coagulation. Ann Thorac Surg. 58:1994;799-805
45. Levy J.H., Montes F., Szlam F., Hillyer C.D. The in vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy. Anesth Analg. 90:2000;1076-1079
46. Nicholson S.C., Keeling D.M., Sinclair M.E., Evans R.D. Heparin pretreatment does not alter heparin requirements during cardiopulmonary bypass. Br J Anaesth. 87:2001;844-847
47. Wallock M., Jeske W.P., Bakhos M., Walenga J.M. Evaluation of a new point of care heparin test for cardiopulmonary bypass: the TAS heparin management test. Perfusion. 16:2001;147-153
48. Gravlee G.P., Rogers A.T., Dudas L.M., Taylor R., Roy R.C., Case L.D., et al. Heparin management protocol for cardiopulmonary bypass influences postoperative heparin rebound but not bleeding. Anesthesiology. 76:1992;393-401
49. Beholz S., Grubitzsch H., Bergmann B., Wollert H.G., Eckel L. Hemostasis management by use of Hepcon/HMS: increased bleeding without increased need for blood transfusion. J Thorac Cardiovasc Surg. 47:1999;322-327
50. Spiess B.D., Gillies B.S., Chandler W., Verrier E. Changes in transfusion therapy and reexploration rate after institution of a blood management program in cardiac surgical patients. J Cardiothorac Vasc Anesth. 9:1995;168-173
51. Shore-Lesserson L., Manspeizer H.E., De Perio M., Francis S., Vela-Cantos F., Ergin M.A. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg. 88:1999;312-319
52. Prisco D., Paniccia R. Point-of-Care testing of hemostasis in cardiac surgery. Thromb J. 1:2003;1